Pulmonary arterial hypertension: epidemiology and registries

…, X Jiang, DP Miller, AJ Peacock… - Journal of the American …, 2013 - jacc.org
Peacock has received honoraria for speaking at meetings (nonpromotional) from Actelion,
Bayer, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and United Therapeutics; travel assistance …

Pulmonary hypertension in chronic lung disease and hypoxia

…, H Olschewski, KM Olsson, AJ Peacock… - European …, 2019 - Eur Respiratory Soc
… Conflict of interest: AJ Peacock has received research grants and personal fees from Actelion
Pharmaceuticals, Bayer, GSK, MSD, Pfizer and United Therapeutics, outside the submitted …

Oxygen at high altitude

AJ Peacock - Bmj, 1998 - bmj.com
… Andrew J Peacock … Andrew J Peacock is consultant physician, department of respiratory
medicine, West Glasgow Hospitals University NHS Trust, … Articles by Andrew J Peacock

An epidemiological study of pulmonary arterial hypertension

AJ Peacock, NF Murphy, JJV McMurray… - European …, 2007 - Eur Respiratory Soc
All hospitalisations for pulmonary arterial hypertension (PAH) in the Scottish population were
examined to determine the epidemiological features of PAH. These data were compared …

[HTML][HTML] Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension

…, VV McLaughlin, AJ Peacock… - … England Journal of …, 2015 - Mass Medical Soc
Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …

Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United …

…, SJ Wort, MA Gatzoulis, AJ Peacock - American journal of …, 2012 - atsjournals.org
Rationale: Incident pulmonary arterial hypertension was underrepresented in most pulmonary
hypertension registries and may have a different disease profile to prevalent disease. …

Connective tissue disease–associated pulmonary arterial hypertension in the modern treatment era

R Condliffe, DG Kiely, AJ Peacock… - American journal of …, 2009 - atsjournals.org
Rationale: Pulmonary arterial hypertension in association with connective tissue disease (CTD-PAH)
has historically had a poor prognosis, with a 1-year survival rate among patients …

Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study

…, E Grünig, PM Hassoun, NW Morrell, AJ Peacock… - Circulation, 2013 - Am Heart Assoc
… Dr Peacock has received honoraria for consultations and/or speaking at conferences
from Actelion, Bayer, GlaxoSmithKline, Lilly, Novartis Pfizer, and United Therapeutics and …

Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension

…, JSR Gibbs, PA Corris, AJ Peacock… - American journal of …, 2008 - atsjournals.org
Rationale: The management of chronic thromboembolic pulmonary hypertension (CTEPH)
has changed over recent years with the growth of pulmonary endarterectomy surgery and the …

Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy

…, MM Hoeper, H Olschewski, AJ Peacock… - American journal of …, 2010 - atsjournals.org
Rationale: Pulmonary arterial hypertension (PAH) is a progressive condition with a poor
prognosis. Platelet-derived growth factor receptor (PDGFR) signaling plays an important role in …